Preeclampsia Prophylaxis
Low-dose aspirin (81-160 mg daily) should be initiated before 16 weeks of gestation (ideally between 12-16 weeks) in pregnant women with high-risk factors for preeclampsia, and continued until 36 weeks of gestation.
Risk Stratification and Identification
The USPSTF and ACOG identify specific high-risk factors that warrant aspirin prophylaxis 1:
High-risk factors (any single factor qualifies):
- History of preeclampsia, especially early-onset (<34 weeks) or in multiple pregnancies
- Chronic hypertension
- Type 1 or type 2 diabetes
- Renal disease
- Autoimmune disease (e.g., lupus, antiphospholipid syndrome)
- Multifetal gestation
Moderate-risk factors (≥2 factors required):
- First pregnancy
- Maternal age ≥40 years
- Pregnancy interval >10 years
- BMI ≥35 kg/m²
- Family history of preeclampsia
The Society for Maternal-Fetal Medicine recommends using systematic checklists to ensure no risk factors are overlooked during prenatal screening 2.
Aspirin Dosing and Timing
Optimal dosing: Network meta-analysis demonstrates that 80-100 mg/day provides the best preventive effect (OR 0.51,95% CI 0.36-0.72) 3. While the traditional U.S. recommendation is 81 mg daily, international guidelines increasingly recommend 100-160 mg daily 4, 5. The French guidelines specifically recommend 100-160 mg daily based on moderate-quality evidence 4.
Critical timing considerations:
- Start before 16 weeks (ideally 12-16 weeks) - this is crucial for efficacy 1, 4
- Do not initiate after 20 weeks - effectiveness is substantially reduced 4
- Continue until 36 weeks of gestation 4
Evidence of Benefit
Aspirin reduces:
The benefit is most pronounced for preterm preeclampsia (<37 weeks), which carries the highest maternal and fetal morbidity 6.
Important Caveats and Limitations
The chronic hypertension paradox: Despite guideline recommendations, recent real-world data shows aspirin initiated at 12-16 weeks did not reduce superimposed preeclampsia in women with chronic hypertension (35.5% vs 34.3%, p=0.79) 7. Paradoxically, severe preeclampsia actually increased in the aspirin group. This suggests the pathophysiology of superimposed preeclampsia may differ from de novo preeclampsia, and aspirin alone may be insufficient in this population.
For chronic hypertension specifically: Consider that aspirin may need to be combined with other interventions, though current evidence for low molecular weight heparin combination therapy remains weak 4. The standard aspirin recommendation persists in guidelines, but clinicians should counsel patients with chronic hypertension that benefits may be limited.
Multiple pregnancy considerations: Emerging evidence suggests higher doses (≥150 mg/day) may be needed for twin/multiple pregnancies due to increased placental burden 8, though this remains investigational.
Safety Profile
Low-dose aspirin does not increase risk of:
- Placental abruption
- Postpartum hemorrhage
- Fetal intracranial bleeding
- Perinatal mortality 1
No developmental harms identified in offspring by 18 months 1.
What NOT to Do
- Do not use aspirin in general low-risk populations - the absolute benefit is minimal and universal prophylaxis is not supported by adequately powered trials 9
- Do not rely on biomarkers alone (sFlt-1/PlGF ratio) for screening or management decisions to reduce morbidity - insufficient evidence 4
- Do not add LMWH routinely to aspirin in high-risk women - no additional benefit demonstrated 4
Post-Pregnancy Implications
Women with preeclampsia history have significantly increased lifetime cardiovascular risk and require long-term follow-up for hypertension, stroke, renal dysfunction, and metabolic disorders 6, 4. This should be clearly communicated and documented for primary care follow-up.